900–1,500 mg/day split into 2–3 doses with meals (better tolerated when divided).
Improves blood sugar control (HbA1c and glucose), sometimes comparable to oral drugs; study quality varies.
View the study (meta-analysis) →Lowers total cholesterol, LDL and triglycerides.
View the study (meta-analysis) →Multiple trials: improves insulin resistance, lowers testosterone, raises SHBG and lowers LH in women with PCOS. Efficacy comparable to metformin with better GI tolerance.
View the study (Grade B) →Helps somewhat with weight loss and improves metabolic markers.
View the study (RCT) →⏱ 3 min read
Berberine is one of those compounds that researchers have studied for decades without the world paying much attention, until its pharmacological profile began to prompt comparisons with metformin, the most prescribed drug in the world for type 2 diabetes, and things changed radically; because berberine activates many of the same mechanisms as metformin, lowers blood glucose with comparable efficacy, improves lipid profiles, reduces inflammation, and shows anti-aging activity in multiple models, all with a relatively favorable safety profile and a plant origin that makes it available without a prescription in most of the world.
Berberine is an isoquinoline alkaloid found in the roots, stems, rhizomes, and bark of a variety of plants, including goldenseal, Amur cork tree, Chinese barberry, and several species of the genus Berberis; it has been used for centuries in the traditional medicine systems of India, China, and Persia to treat gastrointestinal infections, inflammation, and metabolic disorders, and modern scientific research has begun to identify the molecular mechanisms that could explain these historical therapeutic effects.
The evidence on berberine's antidiabetic effects is the most consistent and replicated of its entire pharmacology: a randomized clinical trial comparing berberine, metformin, and rosiglitazone in 97 people with type 2 diabetes over two months found that berberine at one gram per day reduced fasting glucose by 26 percent and hemoglobin A1c by 18 percent, effects comparable to those of the two reference drugs, although the oral bioavailability of berberine is remarkably low, under one percent in some studies, which raises questions about its mechanism of action and about how to optimize its delivery.
A more recent meta-analysis that included studies with more than 2,500 participants with diabetes found that berberine combined with lifestyle modifications reduced HbA1c, normalized circulating lipids, and lowered blood pressure better than lifestyle modifications alone, although the authors noted the methodological heterogeneity of the studies and the need for higher-quality trials to confirm these findings robustly enough to support clinical recommendations.
The effects of berberine on circulating lipids are consistent in both animal models and clinical trials: the compound reduces total cholesterol, LDL, and triglycerides and increases HDL through mechanisms that differ from those of statins, which has led to research into its combined use with these drugs to achieve greater lipid reductions with a lower risk of side effects; a comparative trial with more than 200 participants found that a supplement containing berberine, policosanols, and red yeast rice reduced LDL by almost 32 percent, superior to the 25 percent achieved with ezetimibe and with fewer adverse effects reported.
Berberine acts on multiple pathways that promote neuroprotection and central nervous system health: in animal models of Parkinson's disease, daily administration of berberine prevented damage to dopaminergic neurons and improved short-term memory; in models of depression, it modulated serotonin, dopamine, and norepinephrine levels and reversed the depressant effects of corticosterone by increasing hippocampal synthesis of BDNF, the neurotrophic factor whose relationship with mood and antidepressant response is widely documented.
The main mechanism through which berberine exerts many of its effects is the activation of AMPK, the AMP-activated protein kinase that acts as the master sensor of cellular energy status; this mechanism is also the one it shares with metformin, and it explains why both compounds show such similar effects on glucose metabolism, insulin sensitivity, and the reduction of oxidative stress; the joint activation of AMPK and p38 by berberine also activates Nrf2, a regulator of the expression of cytoprotective proteins that defend the cell against oxidative and inflammatory damage.
The differences between berberine and metformin are also relevant: berberine exhibits lipid effects that metformin does not share to a comparable degree, it does not appear to block muscle adaptations to exercise as consistently as metformin does, and it has a mechanism for lowering LDL cholesterol that is distinct from that of statins, which opens the possibility of using it in combination with both classes of drugs to achieve additive effects with different and potentially complementary safety profiles.
Information, not medical advice. Scientific evidence reflects the quality of the studies.